Menu
Enrolling by invitation NCT05685303

Alleviant ALLAY-HF Study

No phase Interventional Heart Failure

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Alleviant ALV1 System, Sham-Control.
Who it may be relevant to
Registry conditions: Heart Failure. Basic parameters: from 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Australia, Austria, Belgium, Bulgaria +10
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients With Chronic Heart Failure

Overview

Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

Interventions

  • Device Alleviant ALV1 System
    Creation of interatrial shunt
  • Other Sham-Control
    Cardiac imaging

Primary outcome measures

  • Composite Primary Endpoint [Time frame: 12-month]

Eligibility criteria

Inclusion criteria

  • Symptomatic HFpEF/HFmrEF with LVEF greater than or equal to 40%
  • NYHA Class II, III or ambulatory IV
  • Exercise right heart catheterization\*
  • Elevated left atrial pressure during exercise right heart catheterization (greater than or equal to 25 mmHg)
  • Exercise PVR < 1.8 WU
  • Ongoing stable GDMT

Exclusion criteria

  • Advanced heart failure
  • Presence of a pacemaker
  • Evidence of right heart dysfunction

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Crossover
Masking
Double blind
Primary purpose
Treatment

Study locations

United States · 53 centers
  • University of Alabama — Birmingham
  • Arizona Cardiovascular Research Center — Phoenix
  • Pima Heart and Vascular — Tucson
  • Memorial Care Long Beach Medical Center — Long Beach
  • UC Davis Medical Center — Sacramento
  • Scripps Clinical Research Services — San Diego
  • San Francisco VA — San Francisco
  • University of California San Francisco — San Francisco
  • … and 45 more centers
Germany · 9 centers
  • Heart and Vascular Center-Bad Bevensen — Bad Bevensen
  • Herz- und Gefasszentrum Bad Bevensen — Bad Bevensen
  • University of Gießen — Giessen
  • Marienkrankenhaus — Hamburg
  • Askelepios Klinik Altona — Hamburg
  • St. Vincentius Kliniken — Karlsruhe
  • Universitatsklinikum Schleswig-Holstein (UKSH) — Lübeck
  • Universitätsklinikum Kardiologie — Magdeburg
  • … and 1 more center
Spain · 7 centers

Center list to be confirmed — check the primary protocol.

Poland · 6 centers

Center list to be confirmed — check the primary protocol.

Belgium · 3 centers
  • OLV Hospital — Aalst
  • ZAS Middelheim — Antwerp
  • AZ Sint Jan Brugge — Bruges
Bulgaria · 3 centers
  • University Hospital UMHAT Sveti Georgi — Plovdiv
  • Acibadem City Clinic University Tokuda Hospital — Sofia
  • Acibadem City Clinic Cardiovascular Center Sofia — Sofia
Canada · 3 centers
  • Southlake Regional Hospital Centre — Newmarket
  • Centre hospitalier de l'Universite de Montreal (CHUM) — Montreal
  • Centre Integre Universitaire de Sainte et de Services Scoiiaux de l'Estrie - Centre Hospit — Montreal
Israel · 3 centers
  • Shaare Zedek Medical Center — Jerusalem
  • Tel Aviv Sourasky Medical Center — Tel Aviv
  • Shamir Medical Center — Zrifin
Australia · 2 centers
  • Monash Health Victorian Heart Hospital — Clayton
  • Austin Hospital — Heidelberg
Italy · 2 centers

Center list to be confirmed — check the primary protocol.

New Zealand · 2 centers

Center list to be confirmed — check the primary protocol.

Austria · 1 center
  • Medizinische Universität Graz — Graz
Czechia · 1 center
  • Kardiocentrum Nemocnice AGEL Trinec-Podlesi — Třinec
Georgia · 1 center
  • Tbilisi Heart and Vascular — Tbilisi
Greece · 1 center
  • European Interbalken Medical Center — Thessaloniki

Identifiers

NCT: NCT05685303 · CIP-0003

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗